Skip to main content

Table 1 Oncologist characteristics in the physician survey and medical records review studies

From: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

 

Physician survey

Medical records review

Characteristic

Rounds 1 & 2

(N = 301)

Round 3

(N = 152)

Total

(N = 453)

Rounds 1 & 2

(N = 79)

Round 3

(N = 40)

Total

(N = 119)

Country, n (%)

 France

89 (29.6)

39 (25.7)

128 (28.3)

23 (29.1)

11 (27.5)

34 (28.6)

 Germany

79 (26.2)

43 (28.3)

122 (26.9)

26 (32.9)

11 (27.5)

37 (31.1)

 Italy

46 (15.3)

29 (19.1)

75 (16.6)

6 (7.6)

4 (10.0)

10 (8.4)

 Spain

44 (14.6)

22 (14.5)

66 (14.6)

8 (10.1)

4 (10.0)

12 (10.1)

 Czech Republic

18 (6.0)

6 (3.9)

24 (5.3)

5 (6.3)

3 (7.5)

8 (6.7)

 Belgium

6 (2.0)

6 (3.9)

12 (2.6)

3 (3.8)

3 (7.5)

6 (5.0)

 Denmark

5 (1.7)

2 (1.3)

7 (1.5)

3 (3.8)

1 (2.5)

4 (3.4)

 Netherlands

9 (3.0)

3 (2.0)

12 (2.6)

2 (2.5)

1 (2.5)

3 (2.5)

 Sweden

5 (1.7)

2 (1.3)

7 (1.5)

3 (3.8)

2 (5.0)

5 (4.2)

Type of institution, n (%)

 General or regional hospital

91 (30.2)

42 (27.6)

133 (29.4)

20 (25.3)

12 (30.0)

32 (26.9)

 Oncology clinic/institute

30 (10.0)

9 (5.9)

39 (8.6)

7 (8.9)

5 (12.5)

12 (10.1)

 Private clinic/hospital

50 (16.6)

25 (16.4)

75 (16.6)

33 (41.8)

11 (27.5)

44 (37.0)

 University or teaching/training hospital

125 (41.5)

70 (46.1)

195 (43.0)

13 (16.5)

7 (17.5)

20 (16.8)

 Other

5 (1.7)

6 (3.9)

11 (2.4)

6 (7.6)

5 (12.5)

11 (9.2)

Size of institution, no. of inpatient bedsa

493.6 (465.6)

623.9 (434.5)

538.2 (475.6)

316.9 (525.4)

640.2 (570.7)

422.6 (559.0)

 Mean (SD)

400.0

500.0

500.0

50.0

455.0

250.0

 Median (Q1–Q3)

(100.0–772.5)

(310.0–895.5)

(150.0–800.0)

(17.0–400.0)

(250.0–750.0)

(23.0–625.0)

Size of oncology dept., no. of inpatient bedsa

    

39.2 (51.4)

 

 Mean (SD)

NR

38.6 (58.5)

NR

30.0

 Median (Q1–Q3)

NR

24.5 (14.0–45.0)

NR

(15.0–40.0)

No. of years’ experience as a practising oncologist specialising in mCRC

 Mean (SD)

12.5 (7.1)

13.1 (6.7)

12.7 (7.0)

15.7 (8.5)

13.9 (5.9)

15.1 (7.7)

 Median (Q1–Q3)

11.0 (7.0–16.0)

12.0 (8.0–18.0)

12.0 (7.0–17.0)

15.0 (10.0–20.0)

14.0 (10.0–17.5)

15.0 (10.0–20.0)

No. of patients with mCRC treated by the oncologist in the previous 3 months

 Mean (SD)

59.0 (57.7)

53.1 (44.6)

57.1 (53.7)

58.0 (69.0)

37.5 (54.9)

51.1 (65.1)

 Median (Q1–Q3)

40.0 (25.0–70.0)

40.0 (30.0–60.0)

40.0 (25.0–65.0)

36.0 (20.0–70.0)

28.0 (20.0–40.0)

30.0 (20.0–50.0)

No. of patients with mCRC treated with panitumumab in the last 6 months

 Mean (SD)

NR

NR

NR

9.2 (9.1)

6.7 (5.6)

8.4 (8.2)

 Median (Q1–Q3)

NR

NR

NR

6.0 (5.0–10.0)

5.0 (3.0–9.0)

6.0 (5.0–10.0)

  1. mCRC metastatic colorectal cancer, NR not recorded, Q quartile, SD standard deviation
  2. aRounds 1 and 2 of the study participants were asked only about the number of inpatient beds in their facility, which could have led to confusion regarding whether they should give the total number of beds in the hospital or in their oncology department. The survey was amended in Round 3 to prevent this confusion by specifically asking about both